TG Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. 

CEO
Michael Sean Weiss
CEOMichael Sean Weiss
Employees
338
Employees338
Headquarters
Morrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded
1993
Founded1993
Employees
338
Employees338

TGTX Key Statistics

Market cap
5.12B
Market cap5.12B
Price-Earnings ratio
11.61
Price-Earnings ratio11.61
Dividend yield
Dividend yield
Average volume
2.32M
Average volume2.32M
High today
$33.50
High today$33.50
Low today
$31.99
Low today$31.99
Open price
$33.42
Open price$33.42
Volume
1.76M
Volume1.76M
52 Week high
$46.48
52 Week high$46.48
52 Week low
$25.28
52 Week low$25.28

Stock Snapshot

With a market cap of 5.12B, TG Therapeutics(TGTX) trades at $32.51. The stock has a price-to-earnings ratio of 11.61.

On 2025-11-08, TG Therapeutics(TGTX) stock moved within a range of $31.99 to $33.50. With shares now at $32.51, the stock is trading +1.6% above its intraday low and -2.9% below the session's peak.

Trading activity shows a volume of 1.76M, compared to an average daily volume of 2.32M.

The stock's 52-week range extends from a low of $25.28 to a high of $46.48.

The stock's 52-week range extends from a low of $25.28 to a high of $46.48.

TGTX News

Simply Wall St 3d
The Bull Case For TG Therapeutics Could Change Following Raised 2025 Outlook and Surging BRIUMVI Sales

TG Therapeutics reported strong third quarter results in the past week, posting revenue of US$161.71 million and net income of US$390.9 million, and raising its...

The Bull Case For TG Therapeutics Could Change Following Raised 2025 Outlook and Surging BRIUMVI Sales
TipRanks 3d
TG Therapeutics Earnings Call: Strong Growth and Positive Outlook

TG Therapeutics ((TGTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks...

Analyst ratings

78%

of 9 ratings
Buy
77.8%
Hold
11.1%
Sell
11.1%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.